Related Experiment Video
Updated: Jun 23, 2026
09:48
Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
SIRT1 and insulin resistance
Fengxia Liang1, Shinji Kume, Daisuke Koya
1Department of Endocrinology & Metabolism, Kanazawa Medical University, Kahoku-gun, Ishikawa, Japan.
Nature Reviews. Endocrinology
|May 21, 2009
Summary
Sirtuin 1 (SIRT1) plays a key role in metabolism and insulin sensitivity. Research suggests SIRT1 may be a therapeutic target for insulin resistance-related diseases like diabetes.
Area of Science:
- Biochemistry
- Metabolic research
- Molecular biology
Background:
- Sirtuin 1 (SIRT1) is a NAD-dependent histone deacetylase linked to calorie restriction and lifespan.
- SIRT1 regulates glucose and lipid metabolism via its deacetylase activity on numerous substrates.
- It influences insulin signaling, impacting glucose homeostasis and insulin sensitivity.
Purpose of the Study:
- To review the role of SIRT1 in insulin resistance.
- To explore the therapeutic potential of SIRT1 for metabolic diseases.
Main Methods:
- Literature review of experimental studies on SIRT1.
- Analysis of SIRT1's involvement in metabolic pathways and insulin signaling.
- Examination of SIRT1's effects in obese mouse models.
Main Results:
- SIRT1 stimulates glucose-dependent insulin secretion and insulin signaling.
- It modulates adiponectin secretion, inflammation, gluconeogenesis, and reactive oxygen species.
- Overexpression of SIRT1 improves glucose homeostasis and insulin sensitivity in obese mice.
Conclusions:
- SIRT1 has a significant role in regulating metabolic processes and insulin resistance.
- SIRT1 activators show promise for treating metabolic syndrome and diabetes mellitus.
- Further clinical studies are needed to confirm SIRT1's therapeutic efficacy in humans.
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...